At the double: leading vape technology brand FEELM shows off two latest advancements in Dubai
FEELM – part of leading atomization technology company SMOORE – exhibited two game-changing innovations, which have been developed to ‘raise product performance’ across the disposable vape category, during a major industry event in the Middle East.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230621395128/en/
(Photo: Business Wire)
Presented at this year’s World Vape Show in Dubai, the brand’s FEELM Max’s ceramic coil and TOPOWER battery technology were created as part of a targeted effort to ‘level up the single-use sector’ and enhance consumer experience.
The pioneering advancements both earned attention from the industry and are already appearing in devices from globally recognised brands. FEELM says each was designed to address a ‘pain point’ of the industry.
FEELM pioneers the disposable sector with two breakthroughs
In the UK, the capacity of vapes should meet the requirement of 2 ml according to TPD directive act. FEELM, as a responsible brand always compliant with laws and regulations, rolls out a groundbreaking technology with which 2 ml disposables showcase higher product performance.
FEELM Max’s ceramic coil has done away with super-absorbent cotton to reduce the amount of e-liquid that goes to waste and increase the puff count of TRPR and TPD compliant 2ml disposables in the UK by as much as 30% - a rise from 600 to at least 800 puffs. Thanks to this innovation, consumers can have an unprecedentedly better vaping experience while using compliant products.
It also reduces impurities by 78% during the heating process, produces air particles that are 55% smaller than mainstream solutions and uses a ‘constant power engine’ that provides a vapour consistency of 95% and a 35% improvement in taste consistency.
The second notable innovation is FEELM’s TOPOWER battery technology. This breakthrough increases the endurance of large e-liquid capacity vapes and can provide over 6,000 puffs without needing to recharge, which allows consumers to get rid of the hassle of charging.
Further, the compact power solution – which offers 30% more capacity – delivers a consistent output which FEELM says will counter the common issue of flavour reduction caused by voltage drop.
TOPOWER also promises a longer shelf life, with 1% power attenuation over six months and 3% power attenuation over a year. This advancement effectively avoids the burn taste and assures a strong consistency of taste, which means every puff consumers take is pleasant.
Speaking on the developments, Rex Zhang, the Assistant President at FEELM, said: “We pride ourselves on being the brand behind the brands and believe our technology has become to vaping what Intel Core processors are to laptops. We aim to elevate the disposable category to a whole new level through innovation– our ceramic coils and TOPOWER battery solution represent two significant successes on this front.”
Rex added that technology will be a ‘critical metric’ on which to measure the winners and losers of the industry moving forward. He said: “The vape category is fuelled by the desire to help adult smokers switch away from cigarettes – but it is built on innovation.”
FEELM Max’s commercialization and admiration from European customers
FEELM Max has helped customers boost business success and earned high praise at the World Vape Show Dubai expo, with some leading brands commenting on the new developments.
Since the launch of HEXA GO with FEELM Max solution in 2022, the sales of HEXA have steadily increased and HEXA GO has become dominant in the Belgian disposable market. Consumers generally give positive feedback on their products’ ‘smooth taste’, ‘strong consistency’, and ‘higher puff counts’.
Mattia Sparacino, CEO and founder of KIWI Vapor, said of the FEELM Max ceramic coil: “It’s an amazing technology and I hope it will be accessible to all people one day.”
Commenting on the need for advancement in the vape category, John Dunne of the UK Vaping Industry Association said: “Our sector has made significant progress since the first devices hit the market and provided adult smokers with a less harmful alternative to cigarettes.
“We must continue to capitalise on the innovative spirit of our community and invest in new and exciting technologies that can help on the journey to a smoke-free future.”
About FEELM
As a flagship tech brand belonging to SMOORE, FEELM is the world’s leading closed vape system solution provider. Based on the world's leading Ceramic Coil Heating Technology, FEELM combines authentic Flavor Reproduction Technology with innovative electronics technology, bringing ultimate sensation and premium vaping experience.
About SMOORE
Founded in 2009, SMOORE is a global leader in atomization technology solutions, covering reduced-risk products, medical, pharmaceutical, and beauty atomization technologies. With inter-disciplinary atomization research and a diverse product portfolio, SMOORE is committed to becoming an advanced platform, aspired to make life better.
With continuous R&D investment and leading manufacturing capacity, SMOORE has 14 technology research centers worldwide and products are available in more than 50 countries and regions. SMOORE announced IPO in Hong Kong on July 10, 2020.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230621395128/en/
Contact information
Claudia Liu
86 13974468623
mengmeng.liu@smooretech.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom